Senolytic peptide FOXO4-dri selectively removes senescent cells from in vitro expanded human chondrocytes
FDAs 2026 assessment found insufficient clinical safety information and insufficient evidence to establish effectiveness
When you work with one of our products, from BPC-157 to more complex compounds like Tesamorelin or Semax Amidate, you can be confident that the molecule is precisely what it's supposed to be
2026 design paper and in the Lilly disclosures, is that glucagon-receptor agonism drives degradation of PCSK9, which in turn lowers circulating LDL
It is used to treat calcium deficiencies, support bone health, prevent osteoporosis, aid in muscle function, and regulate nerve function
Building trust requires radical transparency about what is known, what is inferred, and what remains unknown